954 Stock Overview
Produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Changmao Biochemical Engineering Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.44 |
| 52 Week High | HK$0.61 |
| 52 Week Low | HK$0.35 |
| Beta | 0.63 |
| 11 Month Change | 1.15% |
| 3 Month Change | 17.33% |
| 1 Year Change | -16.98% |
| 33 Year Change | -36.23% |
| 5 Year Change | -43.59% |
| Change since IPO | -42.86% |
Recent News & Updates
Recent updates
Further Upside For Changmao Biochemical Engineering Company Limited (HKG:954) Shares Could Introduce Price Risks After 25% Bounce
Sep 23
Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist
Aug 02Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled
Nov 18We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability
Apr 28Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns
Aug 03Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital
May 04Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield
Feb 23Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?
Jan 26
A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary
Dec 02Shareholder Returns
| 954 | HK Chemicals | HK Market | |
|---|---|---|---|
| 7D | -4.3% | 0.08% | 0.4% |
| 1Y | -17.0% | 8.0% | 12.0% |
Return vs Industry: 954 underperformed the Hong Kong Chemicals industry which returned 8% over the past year.
Return vs Market: 954 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 954 volatility | |
|---|---|
| 954 Average Weekly Movement | 6.8% |
| Chemicals Industry Average Movement | 6.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 954 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 954's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 647 | Chun Pan | changmaobio.todayir.com |
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, America, and internationally. The company offers fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, medical intermediaries, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. It is also involved in the research and development of medicine and nutraceutical products; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou City, the People's Republic of China.
Changmao Biochemical Engineering Company Limited Fundamentals Summary
| 954 fundamental statistics | |
|---|---|
| Market cap | HK$243.66m |
| Earnings (TTM) | -HK$117.15m |
| Revenue (TTM) | HK$703.16m |
0.3x
P/S Ratio-2.0x
P/E RatioIs 954 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 954 income statement (TTM) | |
|---|---|
| Revenue | CN¥654.27m |
| Cost of Revenue | CN¥615.40m |
| Gross Profit | CN¥38.88m |
| Other Expenses | CN¥147.88m |
| Earnings | -CN¥109.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 5.94% |
| Net Profit Margin | -16.66% |
| Debt/Equity Ratio | 84.2% |
How did 954 perform over the long term?
See historical performance and comparison